Investigation of drug specific cytotoxic T cell in severe cutaneous adverse drug reaction

Investigation of drug specific cytotoxic T cell in severe cutaneous adverse drug reaction - Investigation of drug specific cytotoxic T cell in severe cutaneous adverse drug reaction

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009708

Enrollment

Registered

2013-01-07

Start date

2013-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stevens-Johnson syndrome Toxic epidermal necrolysis

Interventions

Stevens-Johnson syndrome Toxic epidermal necrolysis Healthy control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with Stevens-Johnson syndrome or toxic epidermal necrolysis

Exclusion criteria

Exclusion criteria: Patient regarded as inadequate

Design outcomes

Primary

Measure	Time frame
1. Proliferation of drug specific cytotoxic T cell 2. Cytotoxicity of drug specific T cell against cells expressing specific HLA type 3. Cytokine production of drug specific cytotoxic T cell 4. Repertoire of T cell receptor	—

Countries

Japan

Contacts

Public ContactTomoya Watanabe

Yokohama City University Graduate School of Medicine Environmental Immuno-Dermatology

nabetomo0968@yahoo.co.jp045-787-2675

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026